Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Onco-Innovations Ltd. ( (TSE:ONCO) ) is now available.
Onco-Innovations Limited attended the University of Alberta’s 2025 Innovation Awards, marking the first inclusion of technology licensees, which underscores the university’s emphasis on industry collaboration. Onco-Innovations has an exclusive license to develop and commercialize the PNKP Inhibitor Technology, a significant advancement in cancer treatment that enhances the effectiveness of DNA-damage-based therapies. This collaboration highlights the company’s commitment to translating academic research into therapeutic applications, potentially redefining cancer treatment by targeting DNA repair pathways.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company focused on oncology, dedicated to cancer research and treatment. The company aims to prevent and treat cancer through pioneering research and innovative solutions, holding an exclusive license to patented technology targeting solid tumors.
Average Trading Volume: 35,699
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$79.79M
For detailed information about ONCO stock, go to TipRanks’ Stock Analysis page.